loading page

8-year outcomes of aortic valve replacement with the Carpentier-Edwards PERIMOUNT Magna Ease valve
  • +7
  • Steven Tsui,
  • Michael Rosenbloom,
  • James Abel,
  • Jeffrey Swanson,
  • Axel Haverich,
  • Joseph Zacharias,
  • Gilbert Schorlemmer,
  • Gideon Cohen,
  • Michael Moulton,
  • Ruediger Lange
Steven Tsui
Papworth Surgery

Corresponding Author:[email protected]

Author Profile
Michael Rosenbloom
Cooper University Health Care
Author Profile
James Abel
Saint Paul's Hospital
Author Profile
Jeffrey Swanson
Providence Saint Vincent Medical Center
Author Profile
Axel Haverich
Medizinische Hochschule Hannover
Author Profile
Joseph Zacharias
Blackpool Victoria Hospital
Author Profile
Gilbert Schorlemmer
Saint Marks Hospital
Author Profile
Gideon Cohen
Sunnybrook Health Sciences Centre
Author Profile
Michael Moulton
University of Nebraska Medical Center
Author Profile
Ruediger Lange
Deutsches Herzzentrum Munchen
Author Profile


Introduction The Carpentier-Edwards PERIMOUNT Magna Ease valve is a third-generation bioprosthesis for aortic valve replacement (AVR). This is a postapproval study reporting on its 8‑year outcomes. Methods Adults undergoing AVR with the Magna Ease valve between October 2007 and December 2012 were enrolled for this prospective, nonrandomized, single‑arm, multicenter study. Assessments occurred preoperatively, at hospital discharge, 6 months, 1 year, and annually thereafter up to 8 years. Outcomes included safety endpoints, hemodynamic performance, and New York Heart Association (NYHA) Functional Class. Results Of the 258 study patients, 67.5% were in NYHA Class I or II, and 32.5% were in NYHA Class III or IV at baseline. Concomitant procedures were performed in 44.2%. Total follow-up was 1,597.6 patient-years, median follow‑up was 7 years (interquartile range: 5.5–8.0 years). Eight years following AVR, functional class remained improved from baseline with 93.9% in NYHA Class I/II and 6.1% in NYHA Class III; thirty-eight deaths had occurred, eight of which were valve related; freedom from all‑cause mortality was 80.7% (95% confidence intervals 74.9, 86.4); freedom from valve-related mortality was 95.8% (92.8, 98.8); freedom from reintervention, explant, major bleeding events, and structural valve deterioration were 89.8% (85.1, 94.6), 94.8% (91.7, 97.9), 85.1% (80.0, 90.1), and 90.1% (84.7, 95.4), respectively; effective orifice area was 1.5±0.5 cm 2, mean gradient was 14.8±8.3 mmHg, and 88.6% of patients had no or trivial aortic regurgitation. Conclusions This study demonstrated satisfactory safety and sustained hemodynamic and functional improvements at 8 years following AVR with the Magna Ease valve.
07 Oct 2022Submitted to Journal of Cardiac Surgery
07 Oct 2022Submission Checks Completed
07 Oct 2022Assigned to Editor
10 Oct 2022Reviewer(s) Assigned
29 Oct 2022Editorial Decision: Accept